APLS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Apellis Pharmaceuticals Inc (APLS) does not currently present a strong buy opportunity for a beginner investor with a long-term strategy. While there are some positive catalysts, such as hedge fund buying and optimism around Syfovre's long-term potential, the stock's technical indicators, financial performance, and mixed analyst ratings suggest a cautious approach. Given the lack of strong proprietary trading signals and the investor's preference for long-term investment, holding off on buying until clearer positive trends emerge is advisable.
The technical indicators for APLS are bearish. The MACD is below 0 and negatively contracting, the RSI is neutral at 28.51, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with the nearest pivot at 21.177 and current price at 19.79.
Hedge funds are buying, with a 132.99% increase in buying activity over the last quarter. Analysts like H.C. Wainwright and BofA are optimistic about Syfovre's long-term potential and Empaveli's commercial prospects. Gross margin improved to 85.13%, and net income losses narrowed significantly in Q4 2025.
Analyst ratings are mixed, with some lowering price targets and expressing concerns about slower-than-expected product ramps. Technical indicators are bearish, and options data reflects a negative sentiment.
In Q4 2025, revenue decreased by 5.94% YoY to $199.91M. However, net income improved significantly, narrowing losses by 62.16% YoY to -$58.95M. EPS also improved by 62.07% YoY to -0.47, and gross margin increased to 85.13%, up 5.38% YoY. While there are signs of operational improvement, the company is still not profitable.
Analyst ratings are mixed. Positive ratings include H.C. Wainwright raising the price target to $48 and BofA upgrading to Buy with a $28 target, citing long-term potential. However, firms like Wedbush and Citi have lowered price targets, citing slower growth and flat pricing expectations. The consensus view is neutral to cautiously optimistic, with significant divergence in price targets.
